Since, the reduction in breast cancer deaths due to extending endocrine therapy to 10 years is minimal, the decrease in contralateral breast cancers may provide a more compelling support for extended endocrine therapy for younger women with ER+/HER2- cancers. This evidence concerns the gene ESR1 and breast carcinoma.